New findings reported in JAMA Network Open from a longitudinal cohort study utilizing electronic health records (EHRs) show that individuals with a prior serious mental illness (SMI), including ...
On a clinical level, the study suggests that physicians prescribing Lumakras should remain vigilant for early signs of ILD, especially in patients with lung comorbidities. Additionally, biomarker ...
The value-based contracts tend to be layered on to other contracts, Cruz explained. The PBM and health plan may agree on an ...
“What's going to happen is the PBMs won't be able to meet their rebate guarantees, so they're renegotiating rebate guarantees,” Cruz, a pharmacy benefit consultant for Milliman, said in an interview ...
More than half of melanoma patients whose cancer initially responds to immunotherapy will eventually see their disease return ...
AI and virtual care revolutionize dermatology, enhancing melanoma detection, expanding patient access and improving ...
Livdelzi improved or maintained liver stiffness in up to 85% of PBC patients, with significant reductions in high-risk groups. As a second-line therapy, Livdelzi showed efficacy in reducing alkaline ...
Eli Lilly and Novo Nordisk will lower prices for GLP-1 drugs, aligning with new drug pricing initiatives and Medicare Part D pilot coverage starting April 2026. Lilly's Zepbound and orforglipron will ...
Muscle-invasive bladder cancer management is challenging for cisplatin-ineligible patients due to limited treatment options and high recurrence rates. The Padcev-Keytruda combination therapy ...
Direct-to-consumer drug sales aim to simplify pricing and increase transparency by allowing patients to buy directly from ...
The national five-year survival rate for lung cancer has climbed to nearly 30%, up from 18% from eight years ago, according to the American Lung Association.
Melissa Hanna, J.D., MBA, co-founder and CEO of Mahmee, was one of Managed Healthcare Executive’s 2021 Emerging Leaders in Healthcare. Four years later, she continues to lead the company as it expands ...